Regenity Biosciences
Öystein Valberg has a diverse work experience spanning over several decades. Oystein started their career in the Norwegian Armed Forces as a 2nd Lieutenant from April 1988 to July 1990. From there, they joined Grant Thornton as a CPA and Senior Auditor from September 1996 to April 1998. Oystein then joined US Bank as a Senior Financial Analyst from April 1998 to February 1999.
In February 1999, Valberg joined Medtronic, where they took on various roles. Oystein served as Manager of Investor Relations from February 1999 to October 2000. Oystein then became a Senior Mergers and Acquisitions Associate from October 2000 to October 2004. From October 2004 to April 2006, they served as Plant Controller and Director of Finance. Finally, they became CFO and Controller, Director of Finance from October 2006 to April 2008.
Valberg rejoined Medtronic again in April 2008, this time as the Sr. Director of Finance and Head of Mergers and Acquisitions. Oystein held this position until May 2015 when they were promoted to CFO and Vice President of Finance, Strategy, and Business Development for the Medtronic Surgical Technologies Division. Oystein led a large team responsible for planning, budgeting, and executing the division's annual operating plan. Oystein also led the strategic planning process and the business development function for the division.
In 2016, Valberg transitioned to Regenity Biosciences, where they currently hold the position of CFO. The duration of this role is ongoing.
Oystein Valberg completed their education in a chronological order. From 1990 to 1994, they attended the University of Minnesota - Carlson School of Management and earned a Bachelor of Science degree in Finance. Following that, they pursued further studies at the Burgundy School of Business - BSB from 1992 to 1994, focusing on International Business. Finally, they attended the University of Minnesota - Carlson School of Management again in 1995 and 1996, where they obtained a Master of Business Administration (MBA) with a specialization in Finance.
This person is not in any offices
Regenity Biosciences
1 followers
Collagen Matrix is now Regenity Biosciences. Regenity Biosciences advances new frontiers in regenerative science, turning bioabsorbable materials into life-changing solutions. Sought after for our novel resorbable technologies and distinct approach to contract manufacturing and contract development, our team brings the urgency and vision to deliver breakthrough medtech solutions for medical technology and medical device manufacturers of all sizes. Company Background For more than 25 years, Regenity Biosciences has been transforming bioabsorbable materials into regenerative solutions to repair and regenerate tissue and bone we have since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction. Regenity is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Mission & Values Every day, we work to make a material difference in the lives of patients. With people’s health on the line, it’s our duty to act with urgency and diligence. It is this collective ethos that drives us each day to push the boundaries of what’s possible in tissue repair and regeneration. Looking for a Career with Purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our website to learn more about what sets Regenity apart. www.Regenity.com CMIContact@CollagenMatrix.com